ICD-10-PCS 2027 procedure code
XW033FAIntroduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
Short description: Introduce Non-CAR-T Ther in Periph Vein, Perc, New Tech 10
Code last changed in FY2025 (effective October 1, 2024). Source: official FY2027 ICD-10-PCS release from CMS. Page updated September 29, 2026. About our data
About XW033FA
XW033FA is the ICD-10-PCS code for a introduction procedure on the peripheral vein using a percutaneous approach with non-chimeric antigen receptor t-cell immune effector cell therapy (qualifier: new technology group 10). In ICD-10-PCS, introduction means putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.
For a different body part, codes include XW043FA (central vein).
With a different device, use XW0333A (maribavir anti-infective), XW0334A (stem cells, somatic), XW0335A (ifezuntirgene inilparvovec), XW0338A (mineral-based topical hemostatic agent), XW0339A (odronextamab antineoplastic), XW033BA (vancomycin-eluting bone void filler) and 4 more.
It is a non-O.R. procedure that is part of the MS-DRG logic for DRG 018 (Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies), under the surgical category “Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies”.
It was added in FY2025, effective October 1, 2024.
What each character means
- 1. Section
- XNew Technology
- 2. Body System
- WAnatomical Regions
- 3. Operation
- 0Introduction
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
- 4. Body Part
- 3Peripheral Vein
- 5. Approach
- 3Percutaneous
Entry, by puncture or minor incision, of instrumentation through the skin or mucous membrane and any other body layers necessary to reach the site of the procedure
- 6. Device / Substance / Technology
- FNon-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy
Includes: T-cell Antigen Coupler T-cell (TAC-T) Therapy; T-cell Receptor-Engineered T-cell (TCR-T) Therapy; Tumor-Infiltrating Lymphocyte (TIL) Therapy
- 7. Qualifier
- ANew Technology Group 10
Other versions of this procedure
Different body part
Different device / substance / technology
- XW0333AMaribavir Anti-infective
- XW0334AStem Cells, Somatic
- XW0335AIfezuntirgene Inilparvovec
- XW0338AMineral-based Topical Hemostatic Agent
- XW0339AOdronextamab Antineoplastic
- XW033BAVancomycin-eluting Bone Void Filler
- XW033CARecombinant Human Bone Morphogenetic Protein-2 with Collagen Scaffold
- XW033DADonislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension
- XW033MABaricitinib
- XW033NASER-109
MS-DRG v44.0 grouping
All DRGs →Surgical MS-DRGs this procedure can group to, depending on the principal diagnosis's MDC.
MDC PRE · Pre-MDC · Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2025 (effective 10/1/2024): Added
- No changes since FY2025.
Common questions about XW033FA
Is XW033FA a valid ICD-10-PCS code for 2027?
- Yes. XW033FA is valid for inpatient procedures from October 1, 2026 through September 30, 2027.
Is XW033FA an O.R. procedure?
- No. XW033FA is designated non-O.R. in MS-DRG v44.0.
What DRG does XW033FA group to?
- Depending on the principal diagnosis, XW033FA can group to MS-DRG 018.